AI in Resource-Poor Healthcare Settings: A Beacon of Hope

By Sumona Bose

December 12, 2023

Artificial Intelligence: A Game Changer in Healthcare

The transformative power of Artificial Intelligence (AI) in healthcare is undeniable. Primarily, AI, a facet of computer science that replicates intelligent behaviour, comes in two forms. The first, artificial general intelligence, emulates the human mind. The second, artificial narrow intelligence, excels at a single task. Most AI applications in healthcare belong to the latter category.

AI can be utilised in numerous ways within healthcare. Expert systems, for example, can solve specific problems with a high level of competence. Machine learning, an AI subfield, automates data analysis by detecting patterns. Natural language processing (NLP) bridges the divide between human and computer languages, enabling AI to comprehend text. Automated planning and scheduling organise activities to achieve a goal, while image and signal processing handle data from images and signals.

AI’s Promise in Resource-Poor Settings

AI has already proven beneficial in resource-poor settings. For instance, expert systems have been used to forecast cholera outbreaks in South Africa and birth asphyxia in Brazil. Machine learning has predicted dengue fever transmission in Manila, while NLP has been used for disease surveillance and outbreak predictions. AI planning has enhanced primary healthcare services, and signal processing has predicted birth asphyxia using a mobile phone in Nigeria.

However, implementing AI in resource-poor settings is not without challenges. These include the need for high-quality datasets, robust electronic health record systems, and substantial IT infrastructure. There are also ethical considerations around privacy, confidentiality, data security, informed consent, and data ownership. Cultural biases can also be reflected in data and algorithms, potentially exacerbating inequities.

AI’s Challenges and Insights

Despite these challenges, AI holds enormous potential for improving public health outcomes in low-income countries. The widespread use of smartphones, combined with growing investments in supporting technologies like mobile health, electronic medical records, and cloud computing, provide ample opportunities for AI applications. However, transitioning from pilot to scale will require addressing several issues, including legal and ethical questions, understanding local contexts, and developing a robust research agenda.

In conclusion, AI has the potential to significantly improve healthcare in resource-poor settings. However, it’s crucial that we navigate the challenges and ethical considerations carefully to ensure that this promising technology can truly benefit those who need it most.

Reference url

Recent Posts

GLP-1 Medication Access
Expanded GLP-1 Medication Access Through Formulary Updates

By HEOR Staff Writer

May 29, 2026

CVS Caremark's latest formulary changes are poised to strengthen GLP-1 Medication Access for commercial plan members by restoring coverage for select weight-management therapies. Effective October 1, 2026, Zepbound returns as a preferred option on template formularies for sponsors that elect c...
European pharmacists preparation
European Pharmacists Preparation for Health Crisis Response

By João L. Carapinha

May 29, 2026

European pharmacists preparation ensures that community networks remain operational during health crises, enabling continuous patient care amid pandemics and infrastructure failures. The recently published PGEU position paper outlines seven priorities that integrate pharmacies into governance str...
Imfinzi bladder cancer approval
Imfinzi Bladder Cancer Approval Marks Breakthrough in Immunotherapy

By HEOR Staff Writer

May 29, 2026

The Imfinzi bladder cancer approval by the FDA now offers a new immunotherapy option for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer when combined with standard BCG induction and maintenance therapy. This Imfinzi bladder cancer approval stems from the POTOMAC Phase III ...